Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in June 1981 and incorporated on 25th September 1996, Peregrine Pharmaceuticals changed its name from Techniclone Corporation in 2000. Peregrine is a biopharmaceutical company primarily engaged in the research, development, manufacture and commercialisation of biotherapeutics directed towards the treatment of cancer, viruses and other diseases using targeted antibodies (Abs). The company's product development efforts, including those of its partners, have been primarily focused on cancer therapeutics. However, in fiscal 2005, Peregrine began to expand its therapeutic focus beyond cancer into the treatment of infectious diseases.

The following represent Peregrine's key technology platforms:

- tumour necrosis therapy technology (TNT)
- antiphospholipid therapy technology (APT)
- anti-angiogenesis technology (AAT)
- vascular targeting agent technology (VTA) and
- vasopermeation enhancement agent technology (VEA).